ReviewJournal of diabetes investigation2021
Epidemiological characteristics of diabetic kidney disease in Taiwan.
Review in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Exploring the genomic and transcriptomic profiles of glycemic traits and drug repurposing.Journal of biomedical science · 2025Pooled it
- Research progress on ferroptosis in diabetic kidney disease.Frontiers in endocrinology · 2022Pooled it
- Analysis of the association of multidisciplinary team care and education intervention in patients with early-stage diabetic kidney disease in Taiwan.Endocrine journal · 2026Article
- Association Between Low-Dose Aspirin Use and Early Renal Injury Biomarkers in Patients with Type 2 Diabetes Mellitus: A Retrospective Matched Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- The association between family history of hypertension and diabetic kidney disease in patients with diabetes: a cross-sectional study.Frontiers in endocrinology · 2026Article
- The multifaceted modulations by dapagliflozin in preventing hyperglycemia-induced diabetic nephropathy through glucose transporters and PPARα.Journal of diabetes and metabolic disorders · 2025Article
- Prevalence and risk factors of diabetic kidney disease in Malagasy patients with diabetes mellitus: a cross-sectional study at a University Hospital Center in Antananarivo, Madagascar.BMC nephrology · 2025Article
- Article
- Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Microvascular Complications and Cancer Risk in Type 2 Diabetes: A Population-Based Study.Cancers · 2025Article
- The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions.Kidney research and clinical practice · 2025Article
- Exploring the Incidence and Risk Factors of Diabetic Nephropathy in Type 1 Diabetes: Insights from a Retrospective Cohort Study in Northwest China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.JAMA network open · 2024Article
- Determinants of early chronic kidney disease in patients with recently diagnosed type 2 diabetes mellitus: a retrospective study from the Taiwan Diabetes Registry.BMC nephrology · 2024Article
- Design of Machine Learning Algorithms and Internal Validation of a Kidney Risk Prediction Model for Type 2 Diabetes Mellitus.International journal of general medicine · 2024Article
- Determinants of diabetic nephropathy among adult diabetic patients on follow-up at public hospitals in Addis Ababa, Ethiopia: A case-control study.SAGE open medicine · 2024Article
- Risk of rapid progression to dialysis in patients with type 2 diabetes mellitus with and without diabetes-related complications at diagnosis.Scientific reports · 2023Article
- Predicting hyperkalemia in patients with advanced chronic kidney disease using the XGBoost model.BMC nephrology · 2023Article
- Current status of diabetic kidney disease and latest trends in management.Journal of diabetes investigation · 2022Article
- Epidemiological characteristics of diabetic kidney disease in Taiwan.Journal of diabetes investigation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a critical microvascular complication of diabetes. With the continuous increase in the prevalence of diabetes since 2000, the prevalence of DKD has also been increasing in past years. The prevalence of DKD among individuals with type 2 diabetes in Taiwan increased from 13.32% in 2000 to 17.92% in 2014. The cumulative incidence of DKD among individuals with type 1 diabetes in Taiwan was higher than 30% during 1999-2012. DKD is the leading cause of end-stage renal disease (ESRD), with a prevalence of approximately 45% in a population on chronic dialysis in Taiwan. Among individuals with type 2 diabetes, the prevalence of ESRD in the receipt of dialysis also increased from 1.32% in 2005 to 1.47% in 2014. Risk factors for DKD development are age, race, family history, hyperglycemia, hypertension, dyslipidemia, dietary patterns, and lifestyles. Prognostic factors that aggravate DKD progression include age, family history, sex, glycemic control, blood pressure (BP), microvascular complications, and atherosclerosis. This review summarizes updated information on the onset and progression of DKD, particularly in the Taiwanese population. Translating these epidemiological features is essential to optimizing the kidney care and improving the prognosis of DKD in Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.